pancreatic ductal adenocarcinoma

Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression

By MedXY 09/17/2026

This study reveals that CLDN18.2 acquired by CD8+ T cells through trogocytosis impairs their glucose metabolism and cytotoxic function, promoting pancreatic cancer progression and systemic immune senescence. Targeting this axis may enhance immunotherapy efficacy in PDAC.

General Surgery news Oncology

Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma

By MedXY 09/15/2026

This study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-term outcomes.

General Surgery news Oncology

Neoadjuvant Chemotherapy with or without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Impact on Outcomes

By MedXY 08/31/2026

A propensity-matched study shows adding radiotherapy to neoadjuvant chemotherapy improves pathologic response but does not enhance survival or reduce recurrence in resected pancreatic ductal adenocarcinoma.

Gastroenterology news Oncology

Targeting NSUN6 Deficiency to Overcome Immune Suppression in Pancreatic Cancer: Insights into the KDM5A-CCL2-Macrophage Axis

By MedXY 08/21/2026

NSUN6 deficiency in pancreatic cancer promotes immune suppression by enhancing immunosuppressive macrophage infiltration via the KDM5A-CCL2 axis, leading to resistance to immune checkpoint blockade; targeting this pathway offers a promising therapeutic approach.

Gastroenterology news Oncology

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

By MedXY 07/08/2026

This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.

AI Gastroenterology news

AI Radiomics Detects Visually Occult Pancreatic Cancer on CT Nearly 16 Months Before Diagnosis and Outperforms Radiologists

By MedXY 05/04/2026

A multi-institutional AI model identified pre-diagnostic pancreatic cancer on routine CT with meaningful lead time, higher sensitivity than radiologists, longitudinal stability, and externally validated specificity in a low-prevalence setting.